Lead Product(s): LYS-GM101
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 25, 2020
With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogene's lead gene therapy product, LYS-SAF302, currently in clinical phase 2/3.